ResolutionRx Ltd

About ResolutionRx Ltd

ResolutionRx Ltd is a new pharmaceutical company based in Australia, formed on January 11, 2023, by RespireRx. Its mission is to discover and develop medicines for psychiatric and neurological disorders, with a primary focus on treatments for sleep-related breathing disorders such as Obstructive Sleep Apnoea (OSA), addressing conditions that affect millions but have limited treatment options.

Products & Services

Dronabinol for Obstructive Sleep Apnoea (OSA):Repurposing Dronabinol, originally approved in 1985 for anorexia associated with AIDS and chemotherapy-induced nausea and vomiting, for the treatment of OSA. ResolutionRx is developing new formulations and conducting clinical trials to commercialize this cannabinoid-based treatment for sleep-related breathing disorders.

Specialties

Cannabinoid-based treatments Sleep-related breathing disorders Obstructive Sleep Apnoea (OSA) Psychiatric and neurological disorders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 3125000 MR: - FA: US$3,125,000 FAN: 3125000	D: 2023-05-24 FD: 2023-05-24	1 investors
2	RT: Debt Financing T: - FT: Debt Financing	A: 16500000 MR: - FA: 16.5 million FAN: 16500000	D: 2023-02-10 FD: 2023-02-10	1 investors

Series A Latest

2023-05-24

$3.1M

1 investor (Pro only)

Debt Financing 2023-02-10

$16.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jeff E. Margolis

Acting Co-CEO and CFO, Director

T

Ty Burton

Director

R

Rich Purcell

Senior VP Research & Development

M

Marc Radin

Controller

A

Arnold Lippa

Director, Acting Co-CEO and CSO

J

Jeffrey Witkin

Senior Research Fellow

View 6 more team members with Pro

Unlock Full Team Directory

Recent News